Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido; Ciro Gallo; Michelino De Laurentiis; Giancarlo Bisagni; Grazia Arpino; Maria Giuseppa Sarobba; Ferdinando Riccardi; Antonio Russo; Lucia Del Mastro; Francesco Cognetti; Filippo Montemurro; Antonio Bernardo; Adriano Gravina; Francesco Nuzzo; Francesco Perrone

doi:10.1016/S1470-2045

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, Giancarlo Bisagni, Grazia Arpino, Maria Giuseppa Sarobba, Ferdinando Riccardi, Antonio Russo, Lucia Del Mastro, Francesco Cognetti, Filippo Montemurro, Antonio Bernardo, Adriano Gravina, Francesco Nuzzo, Francesco Perrone

Istituto Nazionale Tumori Fondazione G. Pascale

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	474-485
Number of pages	12
Journal	The Lancet Oncology
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045
Publication status	Published - 2018

Access to Document

10.1016/S1470-2045

http://www.sciencedirect.com/science/article/pii/S1470204518301165

Cite this

De Placido, S., Gallo, C., De Laurentiis, M., Bisagni, G., Arpino, G., Sarobba, M. G., Riccardi, F., Russo, A., Del Mastro, L., Cognetti, F., Montemurro, F., Bernardo, A., Gravina, A., Nuzzo, F., & Perrone, F. (2018). Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. The Lancet Oncology, 19(4), 474-485. https://doi.org/10.1016/S1470-2045

De Placido, S, Gallo, C, De Laurentiis, M, Bisagni, G, Arpino, G, Sarobba, MG, Riccardi, F, Russo, A, Del Mastro, L, Cognetti, F, Montemurro, F, Bernardo, A, Gravina, A , Nuzzo, F & Perrone, F 2018, 'Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial', The Lancet Oncology, vol. 19, no. 4, pp. 474-485. https://doi.org/10.1016/S1470-2045

@article{0fb8847384c04dbfb1578aa59dbf558c,

title = "Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial",

author = "{De Placido}, Sabino and Ciro Gallo and {De Laurentiis}, Michelino and Giancarlo Bisagni and Grazia Arpino and Sarobba, {Maria Giuseppa} and Ferdinando Riccardi and Antonio Russo and {Del Mastro}, Lucia and Francesco Cognetti and Filippo Montemurro and Antonio Bernardo and Adriano Gravina and Francesco Nuzzo and Francesco Perrone",

year = "2018",

doi = "10.1016/S1470-2045",

language = "English",

volume = "19",

pages = "474--485",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

AU - De Placido, Sabino

AU - Gallo, Ciro

AU - De Laurentiis, Michelino

AU - Bisagni, Giancarlo

AU - Arpino, Grazia

AU - Sarobba, Maria Giuseppa

AU - Riccardi, Ferdinando

AU - Russo, Antonio

AU - Del Mastro, Lucia

AU - Cognetti, Francesco

AU - Montemurro, Filippo

AU - Bernardo, Antonio

AU - Gravina, Adriano

AU - Nuzzo, Francesco

AU - Perrone, Francesco

PY - 2018

Y1 - 2018

U2 - 10.1016/S1470-2045

DO - 10.1016/S1470-2045

M3 - Article

VL - 19

SP - 474

EP - 485

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -